Assessing the Issue of Comparability in Orphan Drug Development and Market Access
February 7, 2013
The issue of comparability has long been a topic of strategic discussion in the pharmaceutical industry, and it is now becoming a focus point in the orphan drug space.
We have compiled insights on this matter from conversations with industry and from our own research.
Download the report, ‘Assessing the issue of comparability in orphan drug development and market access.’
The report addresses issues like:
■ The impact of comparability on orphan drug development
■ What happens in Europe?
■ Dealing with regulatory frameworks
■ Consequences to market access and patients globally
For more information on this hot topic, check out World Orphan Drug Congress USA
Sign up for updates straight to your inbox.